If we have any methods to widen CI in parallel design with high variance drug? [RSABE / ABEL]

posted by ElMaestro  – Denmark, 2021-02-02 12:12 (1564 d 08:58 ago) – Posting: # 22200
Views: 2,926

Hi libaiyi,

❝ (...) So my quesion is if we have any method to widen the CI like RSABE in cross-over study?


I don't think there is any authority generally willing to widen the acceptance range in parallel trials involving humans (they'd perhaps do it if you were studying pMDI's in vitro etc).

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
172 visitors (0 registered, 172 guests [including 11 identified bots]).
Forum time: 22:11 CEST (Europe/Vienna)

A statistical analysis, properly conducted, is a delicate dissection of
uncertainties, a surgery of suppositions.    Micheal J. Moroney

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5